These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26860612)

  • 1. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis.
    Bello N; Etcheto A; Béal C; Dougados M; Moltó A
    Arthritis Res Ther; 2016 Feb; 18():42. PubMed ID: 26860612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study.
    Moltó A; Etcheto A; Gossec L; Boudersa N; Claudepierre P; Roux N; Lemeunier L; Martin A; Sparsa L; Coquerelle P; Soubrier M; Perrot S; Dougados M
    Ann Rheum Dis; 2018 Apr; 77(4):533-540. PubMed ID: 29183878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register.
    Macfarlane GJ; MacDonald RIR; Pathan E; Siebert S; Gaffney K; Choy E; Packham J; Martin KR; Haywood K; Sengupta R; Atzeni F; Jones GT
    Rheumatology (Oxford); 2018 Nov; 57(11):1982-1990. PubMed ID: 30053166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice.
    Wach J; Letroublon MC; Coury F; Tebib JG
    J Rheumatol; 2016 Nov; 43(11):2056-2063. PubMed ID: 27633820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tender to touch-Prevalence and impact of concomitant fibromyalgia and enthesitis in spondyloarthritis: An ancillary analysis of the ASAS PerSpA study.
    Fitzgerald GE; Maguire S; Lopez-Medina C; Dougados M; O'Shea FD; Haroon N
    Joint Bone Spine; 2022 Nov; 89(6):105420. PubMed ID: 35636706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
    Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and sonographic discrimination between fibromyalgia and spondyloarthopathy in inflammatory bowel disease with musculoskeletal pain.
    Martinis F; Tinazzi I; Bertolini E; Citriniti G; Variola A; Geccherle A; Marchetta A; McGonagle D; Macchioni P
    Rheumatology (Oxford); 2020 Oct; 59(10):2857-2863. PubMed ID: 32068873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis.
    Santos-Faria D; Dougados M; Gossec L; Perrot S; Moltó A
    Rheumatol Int; 2019 Jan; 39(1):141-146. PubMed ID: 30413924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of concomitant fibromyalgia in rheumatic diseases: Monocentric study of 691 patients.
    Fan A; Pereira B; Tournadre A; Tatar Z; Malochet-Guinamand S; Mathieu S; Couderc M; Soubrier M; Dubost JJ
    Semin Arthritis Rheum; 2017 Aug; 47(1):129-132. PubMed ID: 28216193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis.
    Provan SA; Dean LE; Jones GT; Macfarlane GJ
    Rheumatology (Oxford); 2021 Sep; 60(9):4121-4129. PubMed ID: 34469570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
    Krabbe S; Glintborg B; Østergaard M; Hetland ML
    Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASAS Health Index in patients with spondyloarthritis and its association with disease activity and disease burden including fibromyalgia.
    Puche Larrubia MÁ; Castro Villegas MC; Ortega Castro R; Garrido-Castro JL; Font-Ugalde P; Escudero-Contreras A; Ladehesa-Pineda L; Gómez García I; Collantes-Estévez E; López Medina C
    Clin Exp Rheumatol; 2021; 39 Suppl 130(3):82-88. PubMed ID: 33635208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibromyalgia in Spondyloarthritis: Prevalence and Effect on Disease Activity and Treatment.
    Olfa S; Bouden S; Sahli M; Tekaya AB; Rouached L; Rawdha T; Mahmoud I; Abdelmoula L
    Curr Rheumatol Rev; 2023; 19(2):214-221. PubMed ID: 36056847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis.
    Alazmi M; Sari I; Krishnan B; Inman RD; Haroon N
    Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1393-1399. PubMed ID: 29125891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.
    Krajewski F; Andras L; Pereira-Gillion C; Goupille P; Salliot C
    Joint Bone Spine; 2019 Nov; 86(6):761-767. PubMed ID: 31326602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis.
    Dougados M; Logeart I; Szumski A; Coindreau J; Jones H
    Clin Exp Rheumatol; 2017; 35 Suppl 105(3):50-53. PubMed ID: 28240587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of Fibromyalgia Syndrome and Its Relationship with Clinical Parameters in Patients with Axial Spondyloarthritis.
    Rencber N; Saglam G; Huner B; Kuru O
    Pain Physician; 2019 Nov; 22(6):E579-E585. PubMed ID: 31775411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.